~~<i id='C75E976318'><strike id='C75E976318'><tt id='C75E976318'><pre id='C75E976318'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：entertainment 2025-09-30 02:38:54 Page View：582

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dark money group runs ads on China biotech bill
Next article： The cancer drug shortage isn’t new — and neither are the solutions

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

4th of July breaks record for highest global temperature ever measured

1:18AtaxidriversplasheswaterintohisfacetocooloffinadowntownstreetduringahotandsunnydayinTehran,Iran,

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Advancesingenetherapycouldeventually"cure"manyformsofcongenitaldeafness.Thechangeshavemanydeafpeople